Crossmark

Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function

Published Online: 2021-03-25

Published Print: 2021-06

Authors

Mielczarek, Łukasz https://orcid.org/0000-0002-4840-2442
Brodziak, Anna https://orcid.org/0000-0002-0017-1040
Sobczuk, Paweł https://orcid.org/0000-0002-4103-1626
Kawecki, Maciej https://orcid.org/0000-0001-7858-6214
Cudnoch-Jędrzejewska, Agnieszka https://orcid.org/0000-0002-3872-291X
Czarnecka, Anna M. https://orcid.org/0000-0002-2107-3810
Funding

Funding for this research was provided by:

Ministerstwo Nauki i Szkolnictwa Wyższego (Maria Sklodowska-Curie National Research Institute of Oncolog Statutory Founding)
License Information

Text and Data Mining valid from 2021-03-25

Version of Record valid from 2021-03-25
More Information

Article History

Received: 13 December 2020

Accepted: 13 March 2021

First Online: 25 March 2021

Declarations

:

: AB has received a travel grant from Novartis and honoraria from Janssen. PS has received travel grants from MSD, Roche, and Pierre Fabre. AMC has received travel grants and honoraria from BMS, MSD, Roche, and Novartis. ŁM and ACJ declare no conflict of interest.

: This article does not contain any studies with human participants or animals performed by any of the authors.

Document is current